Trial Profile
A pharmacovigilance study to evaluate safety of AVODART (dutasteride) administration 0,5 mg once daily, for 52 weeks, in subjects with benign prostate hyperplasia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Dutasteride (Primary)
- Indications Benign prostatic hyperplasia
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 05 Feb 2008 New trial record.